Screener
UroGen Pharma URGN Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by UroGen Pharma in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: UroGen Pharma’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 8:05 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001437749-26-025794
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 19) | ||
| Shareholders' deficit: | ||
| Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at June 30, 2026 and December 31, 2025; 48,869,530 and 48,350,272 shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | 135 | 133 |
| Additional paid-in capital | 865,112 | 854,090 |
| Accumulated deficit | (997,641) | (959,716) |
| Accumulated other comprehensive income | (2) | 19 |
| Total shareholders' deficit | (132,396) | (105,474) |
| Total liabilities and shareholders' deficit | $252,590 | $200,455 |
Item 1. Financial Statements.
FAQ
- What is UroGen Pharma's retained earnings?
- UroGen Pharma (URGN) reported retained earnings of -$997.64M in Q2 2026.
- How has UroGen Pharma's retained earnings changed year-over-year?
- UroGen Pharma's retained earnings decreased by 10.8% year-over-year, from -$900.01M to -$997.64M.
- What is the long-term trend for UroGen Pharma's retained earnings?
- Over 5 years (2020 to 2025), UroGen Pharma's retained earnings has grown at a 21.9% compound annual growth rate (CAGR), from -$356.5M to -$959.72M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about UroGen Pharma's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude